FR20C1050I1 - - Google Patents

Info

Publication number
FR20C1050I1
FR20C1050I1 FR20C1050C FR20C1050I1 FR 20C1050 I1 FR20C1050 I1 FR 20C1050I1 FR 20C1050 C FR20C1050 C FR 20C1050C FR 20C1050 I1 FR20C1050 I1 FR 20C1050I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42128829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1050(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR20C1050I1 publication Critical patent/FR20C1050I1/fr
Application granted granted Critical
Publication of FR20C1050I2 publication Critical patent/FR20C1050I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR20C1050C 2008-10-31 2020-10-15 Cephalosporine comprenant un groupe catechol Active FR20C1050I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008280828 2008-10-31
EP09823578.1A EP2341053B1 (en) 2008-10-31 2009-10-27 Cephalosporin having catechol group

Publications (2)

Publication Number Publication Date
FR20C1050I1 true FR20C1050I1 (fi) 2020-11-27
FR20C1050I2 FR20C1050I2 (fr) 2021-10-15

Family

ID=42128829

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1050C Active FR20C1050I2 (fr) 2008-10-31 2020-10-15 Cephalosporine comprenant un groupe catechol

Country Status (38)

Country Link
US (1) US9238657B2 (fi)
EP (2) EP2960244B1 (fi)
JP (2) JP5498393B2 (fi)
KR (1) KR101655961B1 (fi)
CN (1) CN102203100B (fi)
AU (1) AU2009310959B2 (fi)
BR (1) BRPI0921701B8 (fi)
CA (1) CA2736953C (fi)
CL (1) CL2011000939A1 (fi)
CO (1) CO6331443A2 (fi)
CR (1) CR20110144A (fi)
CY (2) CY1118536T1 (fi)
DK (1) DK2960244T3 (fi)
EA (1) EA019520B1 (fi)
ES (2) ES2602969T3 (fi)
FI (1) FIC20200039I1 (fi)
FR (1) FR20C1050I2 (fi)
HR (1) HRP20161408T1 (fi)
HU (2) HUE031802T2 (fi)
IL (1) IL211720A (fi)
LT (2) LT2960244T (fi)
MA (1) MA32731B1 (fi)
ME (1) ME02666B (fi)
MX (1) MX2011004636A (fi)
MY (1) MY155655A (fi)
NL (1) NL301067I2 (fi)
NO (1) NO2020035I1 (fi)
NZ (1) NZ591728A (fi)
PE (1) PE20120010A1 (fi)
PL (1) PL2960244T3 (fi)
PT (1) PT2960244T (fi)
RS (1) RS55365B1 (fi)
SI (1) SI2960244T1 (fi)
SM (1) SMT201600397B (fi)
TW (1) TWI535727B (fi)
UA (1) UA105190C2 (fi)
WO (1) WO2010050468A1 (fi)
ZA (1) ZA201102024B (fi)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883772B2 (en) 2007-10-09 2014-11-11 Sopharmia, Inc. Broad spectrum beta-lactamase inhibitors
MX2011004636A (es) * 2008-10-31 2011-06-20 Shionogi & Co Cefarosporinas que tienen un grupo catecol.
CN102918048A (zh) * 2010-04-05 2013-02-06 盐野义制药株式会社 具有儿茶酚基团的头孢烯类化合物
JP5852559B2 (ja) * 2010-04-05 2016-02-03 塩野義製薬株式会社 擬似カテコール基を有するセフェム化合物
WO2011136268A1 (ja) * 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なセフェム誘導体
CN103502218B (zh) * 2011-03-04 2016-08-17 生命科技公司 用于缀合生物分子的化合物和方法
KR101719556B1 (ko) * 2011-03-30 2017-03-24 주식회사 레고켐 바이오사이언스 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물
US9334289B2 (en) * 2011-04-28 2016-05-10 Shionogi & Co., Ltd. Cephem compound having catechol or pseudo-catechol structure
US9242999B2 (en) 2011-06-27 2016-01-26 Shionogi & Co., Ltd. Cephem compound having pyridinium group
JPWO2013051597A1 (ja) 2011-10-04 2015-03-30 塩野義製薬株式会社 カテコール基を有するセフェム誘導体
TWI547496B (zh) * 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
WO2014069649A1 (en) 2012-10-29 2014-05-08 Shionogi & Co., Ltd. Processes for production of intermediates for 2-alkyl cephem compounds
JPWO2014104148A1 (ja) * 2012-12-26 2017-01-12 塩野義製薬株式会社 セフェム化合物
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
WO2015148379A1 (en) 2014-03-24 2015-10-01 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
JP6377570B2 (ja) * 2014-04-28 2018-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２−置換セフェム化合物を含有する医薬組成物
CN109988186A (zh) 2014-06-11 2019-07-09 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
CN106687116B (zh) * 2014-09-04 2020-07-24 盐野义制药株式会社 含有具有儿茶酚基的头孢菌素类的制剂
HUE056038T2 (hu) * 2014-09-04 2022-01-28 Shionogi & Co Cefalosporin-származék sója, annak kristályos szilárd alakja és eljárás annak elõállítására
CN106661052B (zh) * 2014-09-04 2021-05-11 盐野义制药株式会社 头孢菌素衍生物的中间体及其制造方法
US10464896B2 (en) 2015-06-11 2019-11-05 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
EA202092620A1 (ru) 2015-09-23 2021-06-30 Новартис Аг Соли и твердые формы монобактамного антибиотика
CA3005779C (en) 2015-12-10 2020-04-07 Naeja-Rgm Pharmaceuticals Ulc Cephem compounds, their production and use
CN108699059B (zh) 2016-03-08 2021-06-18 诺华股份有限公司 可用于治疗正粘病毒感染的三环化合物
WO2017216765A1 (en) * 2016-06-17 2017-12-21 Wockhardt Limited Antibacterial compositions
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3634471A4 (en) * 2017-06-09 2021-02-24 FOB Synthesis, Inc. CARBAPENEM COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS
EP3661933B1 (en) 2017-08-02 2022-03-23 Novartis AG Process for preparing 1-(((z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid
JP7065989B2 (ja) 2018-02-28 2022-05-12 ノバルティス アーゲー インフルエンザを処置するためのオルソミクソウイルス複製の阻害剤としての１０－（ジ（フェニル）メチル）－４－ヒドロキシ－８，９，９ａ，１０－テトラヒドロ－７Ｈ－ピロロ［１’，２’：４，５］ピラジノ［１，２－ｂ］ピリダジン－３，５－ジオン誘導体および関連化合物
WO2020184399A1 (ja) * 2019-03-08 2020-09-17 塩野義製薬株式会社 抗菌用医薬組成物
KR20220061163A (ko) 2019-09-06 2022-05-12 나브리바 테라퓨틱스 게엠베하 사이드로포어 세팔로스포린 접합체 및 이의 용도
AU2021210472A1 (en) * 2020-01-22 2022-07-21 Jiangsu Hengrui Medicine Co., Ltd. Cephalosporin antibacterial compound and pharmaceutical application thereof
TW202220663A (zh) 2020-07-28 2022-06-01 日商鹽野義製藥股份有限公司 含有具有鄰苯二酚基之頭孢菌素類的凍結乾燥製劑及其製造方法
CA3204655A1 (en) 2021-01-12 2022-07-21 Jian Huang Cephalosporin antibacterial compound and preparation method therefor
CN113698365A (zh) * 2021-08-30 2021-11-26 成都大学 一种头孢地尔侧链的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
JPS57118588A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel cephalosporin
DE3207840A1 (de) 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
GR79784B (fi) 1983-01-21 1984-10-31 Beecham Group Plc
NO165842C (no) 1984-04-23 1991-04-17 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
EP0168177A3 (en) 1984-06-28 1987-04-01 Pfizer Limited Cephalosporin antibiotics
NO166283C (no) 1985-03-01 1991-06-26 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive 7beta-(2-(5-amino-1,2,4-tiadiazol-3-yl)-2(z)-substituertoksyiminoacetamido)-3-(heterocyclylmetyl)-3-cefem-4-karboksylsyrederivater.
JPH068300B2 (ja) * 1985-08-02 1994-02-02 萬有製薬株式会社 新規セフアロスポリン誘導体
EP0211656A3 (en) 1985-08-10 1988-03-09 Beecham Group Plc Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
JPH07107069B2 (ja) * 1985-09-03 1995-11-15 大塚化学株式会社 セフアロスポリン化合物の新規誘導体、その製造法及び該誘導体を含有する医薬組成物
EP0214600B1 (en) * 1985-09-03 1992-12-02 Otsuka Kagaku Kabushiki Kaisha Cephalosporin derivatives
JPS62158291A (ja) * 1986-01-07 1987-07-14 Sagami Chem Res Center セフアロスポリン誘導体
ATE92927T1 (de) 1986-04-14 1993-08-15 Banyu Pharma Co Ltd 1-carboxy-1-vinyloxyiminoaminothiazolcephalosporin-derivate und deren herstellung.
ATE110386T1 (de) * 1986-04-14 1994-09-15 Banyu Pharma Co Ltd Cephalosporinderivate, verfahren zu ihrer herstellung und antibakterielle präparate.
IE61679B1 (en) 1987-08-10 1994-11-16 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
GB8719875D0 (en) 1987-08-22 1987-09-30 Beecham Group Plc Compounds
JPH0228185A (ja) 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその合成中間体
US5149803A (en) 1988-05-10 1992-09-22 Imperial Chemical Industries Plc Intermediates for cephalosporin compounds
GB8811055D0 (en) 1988-05-10 1988-06-15 Ici Plc Antibiotic compounds
PH25965A (en) 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
US5244890A (en) 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GB8813945D0 (en) 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) * 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
CA2005787A1 (en) 1988-12-29 1990-06-29 Masao Wada Cephalosporin compounds
JPH02275886A (ja) 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその製法
US5143910A (en) * 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5126336A (en) 1990-08-23 1992-06-30 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
US5234920A (en) 1990-08-23 1993-08-10 Bristol-Myers Squibb Company Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5095012A (en) 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5194433A (en) 1990-11-13 1993-03-16 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
EP0628562A1 (fr) 1993-06-10 1994-12-14 Roussel Uclaf Céphalosporines comportant en position 7 un radical oxymino substitué, leurs intermédiaires, leurs procédé de préparation et leur application comme médicaments
WO1999033839A1 (en) 1997-12-26 1999-07-08 Cheil Jedang Corporation Cephem derivatives and a method for producing the compounds and an antibacterial composition containing the compounds
ES2246399T3 (es) 2001-03-27 2006-02-16 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahidroisoquinolinas como antagonistas derivados del receptor de urotensina ii.
JP2003078440A (ja) 2001-08-30 2003-03-14 Kyocera Corp 高周波スイッチ回路
TW200305422A (en) 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
WO2003099826A1 (en) 2002-05-23 2003-12-04 Orchid Chemicals And Pharmaceuticals Limited A new process for the preparation of cefditoren using the thioester of thiazolylacetic acid
JP4892926B2 (ja) 2005-10-25 2012-03-07 宇部興産株式会社 スルホン化芳香族ブロック共重合体の製造方法
JP3928086B2 (ja) 2005-03-29 2007-06-13 塩野義製薬株式会社 ３−プロペニルセフェム誘導体
JP4557859B2 (ja) 2005-09-29 2010-10-06 富士通株式会社 周波数分割多重送受信装置及び送受信方法
WO2007096740A2 (en) 2006-02-20 2007-08-30 Orchid Research Laboratories Limited Novel cephalosporins
EP1994035A1 (en) * 2006-03-16 2008-11-26 Astellas Pharma Inc. Cephem compounds and use as antimicrobial agents
MX2011004636A (es) 2008-10-31 2011-06-20 Shionogi & Co Cefarosporinas que tienen un grupo catecol.
CN102918048A (zh) 2010-04-05 2013-02-06 盐野义制药株式会社 具有儿茶酚基团的头孢烯类化合物
JP5852559B2 (ja) 2010-04-05 2016-02-03 塩野義製薬株式会社 擬似カテコール基を有するセフェム化合物
WO2011136268A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なセフェム誘導体

Also Published As

Publication number Publication date
US20110190254A1 (en) 2011-08-04
IL211720A (en) 2015-01-29
BRPI0921701B8 (pt) 2022-06-07
WO2010050468A1 (ja) 2010-05-06
JPWO2010050468A1 (ja) 2012-03-29
PL2960244T3 (pl) 2017-03-31
HUE031802T2 (en) 2017-08-28
NO2020035I1 (no) 2020-10-21
CA2736953C (en) 2017-07-11
AU2009310959A1 (en) 2010-05-06
HRP20161408T1 (hr) 2016-12-02
CL2011000939A1 (es) 2011-09-16
JP2014065732A (ja) 2014-04-17
CN102203100B (zh) 2014-08-27
AU2009310959B2 (en) 2015-05-07
CY2020034I1 (el) 2020-11-25
BRPI0921701A2 (pt) 2020-08-11
DK2960244T3 (en) 2016-11-28
FIC20200039I1 (fi) 2020-10-19
NL301067I2 (nl) 2020-10-28
EP2341053B1 (en) 2016-01-13
KR101655961B1 (ko) 2016-09-08
CA2736953A1 (en) 2010-05-06
PE20120010A1 (es) 2012-02-07
RS55365B1 (sr) 2017-03-31
NL301067I1 (fi) 2020-10-13
MX2011004636A (es) 2011-06-20
EP2960244B1 (en) 2016-09-14
EA019520B1 (ru) 2014-04-30
SI2960244T1 (sl) 2017-02-28
CN102203100A (zh) 2011-09-28
CY1118536T1 (el) 2017-07-12
TW201020259A (en) 2010-06-01
MA32731B1 (fr) 2011-10-02
TWI535727B (zh) 2016-06-01
IL211720A0 (en) 2011-06-30
CR20110144A (es) 2011-09-09
ES2564836T3 (es) 2016-03-29
HUS2000042I1 (hu) 2020-11-30
LT2960244T (lt) 2016-11-25
KR20110090982A (ko) 2011-08-10
ES2602969T3 (es) 2017-02-23
CY2020034I2 (el) 2021-05-05
JP5498393B2 (ja) 2014-05-21
ZA201102024B (en) 2014-08-27
MY155655A (en) 2015-11-13
US9238657B2 (en) 2016-01-19
EA201170632A1 (ru) 2011-12-30
BRPI0921701B1 (pt) 2022-05-03
CO6331443A2 (es) 2011-10-20
EP2960244A1 (en) 2015-12-30
ME02666B (me) 2017-06-20
EP2341053A4 (en) 2012-08-08
UA105190C2 (ru) 2014-04-25
NZ591728A (en) 2012-12-21
EP2341053A1 (en) 2011-07-06
PT2960244T (pt) 2016-11-02
FR20C1050I2 (fr) 2021-10-15
LTPA2020530I1 (lt) 2020-11-10
SMT201600397B (it) 2017-01-10

Similar Documents

Publication Publication Date Title
FR20C1050I1 (fi)
BR112016019572A2 (fi)
BRPI0909040A2 (fi)
BRPI0908549B8 (fi)
BRPI0920750A2 (fi)
BRPI0922455A2 (fi)
BRPI0907698A2 (fi)
BRPI0923734A2 (fi)
BRPI0912727A2 (fi)
BRPI0908285A2 (fi)
BRPI0910485A2 (fi)
BRPI0914750A2 (fi)
BRPI0922669A2 (fi)
BRPI0908120A2 (fi)
BRPI0912462A2 (fi)
BRPI0904541A8 (fi)
BRPI0920914A2 (fi)
BRPI0911617A2 (fi)
BRPI0909508A2 (fi)
BRPI0913605A2 (fi)
CH2352018H2 (fi)
BRPI0910572A2 (fi)
BRPI0914820A2 (fi)
AR073287B1 (fi)
BRPI0923127A (fi)